Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
Comparison of the Effect of Metformin-Sotagliflozin Versus Metformin-Empagliflozin Combination Therapy on Glycemic Control Measured by HbA1c in Patients With Type 2 Diabetes Mellitus
The goal of this randomized controlled trial is to compare two medicines added to metformin for blood sugar control in adults with type 2 diabetes whose HbA1c remains between 7.0% and 10.0% despite a stable dose of metformin. The main question it aims to answer is: Does adding sotagliflozin (a dual SGLT1/SGLT2 inhibitor) lower HbA1c more than adding empagliflozin (a selective SGLT2 inhibitor) after 24 weeks? Participants will continue their usual metformin dose and will be randomly assigned to take either sotagliflozin 200 mg or empagliflozin 10 mg once daily for 24 weeks. They will be reviewed at 4, 12 and 24 weeks for adherence, side effects and adverse events, and HbA1c will be measured at baseline and at 24 weeks.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Pakistan has one of the highest adult diabetes prevalences in the world, and many patients fail to reach HbA1c targets on metformin monotherapy and require a second agent. SGLT2 inhibitors such as empagliflozin are established second-line agents. Sotagliflozin additionally inhibits intestinal SGLT1, blunting post-prandial glucose absorption and enhancing incretin release, which may provide additional glucose lowering. No head-to-head randomized comparison of these two combinations has been performed in Pakistan.
This is a single-centre, open-label, parallel-group randomized controlled trial with blinded outcome assessment, conducted at the Department of Medicine and Diabetic Clinic/Medicine OPD, Allied Hospital-I, Faisalabad Medical University. 140 patients (70 per group) will be enrolled by consecutive sampling and randomized 1:1. Sample size was calculated for 95% confidence, 80% power, SD of HbA1c change 1%, and a minimal clinically important difference of 0.5%, inflated by 10% for loss to follow-up. HbA1c will be measured by a standardized laboratory method at baseline and 24 weeks, with laboratory staff blinded to group allocation. Data will be analysed in SPSS; mean change in HbA1c will be compared using the independent-samples t-test (p ≤ 0.05 significant), with stratification for age, gender, BMI, duration of diabetes and baseline HbA1c.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 4
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Sheraz Ali
- Telefonnummer: +923330360744
- E-mail: sheraz.mirza10@gmail.com
Studiesteder
-
-
Punjab Province
-
Faisalabad, Punjab Province, Pakistan, 38000
- Allied Hospital, Faisalabad Medical University
-
Kontakt:
- Sheraz Ali
- Telefonnummer: 03330360744
- E-mail: sheraz.mirza10@gmail.com
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 30 to 65 years, male or female
- Diagnosed type 2 diabetes mellitus (ADA criteria)
- Inadequately controlled on metformin: stable dose ≥1500 mg/day (or maximum tolerated dose) for at least 8 weeks, with HbA1c ≥7.0% and ≤10.0% at screening
- Willing to provide written informed consent and attend scheduled follow-up
Exclusion Criteria:
- Type 1 diabetes mellitus or secondary diabetes
- Use of any SGLT inhibitor, GLP-1 receptor agonist, DPP-4 inhibitor or sulfonylurea within the previous 8 weeks
- eGFR <45 mL/min/1.73 m², or significant hepatic impairment
- Pregnancy, lactation, or women of childbearing potential not using contraception
- Haemoglobinopathies
- Known hypersensitivity to any study drug, or any condition making the patient unsuitable for the trial
- Recurrent genital/urinary tract infections or history of Fournier's gangrene
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Enkelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Metformin + Sotagliflozin (Group A)
Existing stable dose of metformin plus sotagliflozin 200 mg orally once daily for 24 weeks. |
200 mg tablet orally once daily for 24 weeks continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated) |
|
Aktiv komparator: Metformin + Empagliflozin (Group B)
Existing stable dose of metformin plus empagliflozin 10 mg orally once daily for 24 weeks. |
continued at the participant's existing stable dose (≥1500 mg/day or maximum tolerated) 10 mg tablet orally once daily for 24 weeks |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in HbA1c From Baseline to Week 24
Tidsramme: Baseline and 24 weeks
|
Glycated haemoglobin (%) measured by a standardized laboratory method. Change calculated as baseline HbA1c minus week-24 HbA1c for each participant; a between-group difference ≥0.5% is considered clinically meaningful. |
Baseline and 24 weeks
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Adverse Events
Tidsramme: Up to 24 weeks (assessed at weeks 4, 12 and 24)
|
Adverse events including genital/urinary tract infections, hypoglycaemia and gastrointestinal symptoms, recorded at follow-up visits. |
Up to 24 weeks (assessed at weeks 4, 12 and 24)
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Sheraz Ali, Faisalabad Medical University
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Metaboliske sygdomme
- Glukosemetabolismeforstyrrelser
- Diabetes mellitus
- Ernæringsmæssige og metaboliske sygdomme
- Diabetes mellitus, type 2
- Organiske kemikalier
- Biguanides
- Guanidiner
- Amidiner
- Metformin
- (2S,3R,4R,5S,6R)-2-(4-chlor-3-(4-ethoxybenzyl)phenyl)-6-(methylthio)tetrahydro-2H-pyran-3,4,5-triol
- Empagliflozin
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 48.ERC/FMU/2025-26/434
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared; aggregate results will be published in a peer-reviewed journal.
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .